Need Help?

Breast Cancer - Subtype defined by an amplification of the HER2 gene

Clinically positive HER2 (cHER2+) breast cancers (BC) are defined by the amplification and overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12 and represent 15% of all BCs. Although anti-HER2 targeted therapies have improved BC’s natural history, the magnitude of their benefit varies widely between patients and deciphering the genomic heterogeneity of cHER2+ BC may provide a basis to better understand patients’ outcome. As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 cHER2+ primary invasive carcinomas.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001844 Illumina HiSeq 2000 128
EGAD00001003189 Illumina HiSeq 2000 16
EGAD00010000886 Affymetrix HG_U133_+2 99
EGAD00010000919 HUMANOMNI1QUAD 2
EGAD00010000920 HUMANOMNIEXPRESS 50
EGAD00010000921 CYTOSCANHD 12
Publications Citations
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.
Nat Commun 7: 2016 12222
77
ERα-associated translocations underlie oncogene amplifications in breast cancer.
Nature 618: 2023 1024-1032
16